Press Releases
* Please note that the news release contains the content at the time of the announcement and may differ from the latest information.
February 15, 2016
Euglena Co., Ltd. conducts gene analysis in research and medical fields
Invested in "Amelief Corporation"
Euglena Co., Ltd.
Euglena Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Mitsuru Izumo) is pleased to announce that it has invested in Ameliev Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Masao Yamaguchi, hereinafter Ameliev). ..
Recent advances in analytical equipment have made it possible to obtain vast amounts of genetic information at low cost, and it is expected that genetic information will be used for the prevention and treatment of diseases.
Ameliev possesses highly specialized gene analysis technology, and provides research institutes and medical institutions as customers for contract analysis of genetic information, system development for analyzing genetic information, and training services related to gene analysis. It is a venture company. Ameliev will utilize its gene analysis technology to enable the selection of treatment methods and drugs that can be expected to have high therapeutic effects and suppression of side effects according to the genetic characteristics of each individual, and to use the accumulated knowledge as the mechanism of the disease. We aim to realize a richer and healthier human society by utilizing it for elucidation and development of new drugs.
We are conducting a wide range of research in the field of biotechnology under the corporate vision of "making the impossible of yesterday possible today with biotechnology." Through this investment, we plan to utilize Ameliev's know-how in gene analysis technology for research and development, as well as collaborate in the healthcare business.
The details are as follows.
About investment in Ameliev Co., Ltd.
■ Overview of Ameliev
| (1) Name | Ameliev Co., Ltd. |
| (2) Location | 1-12-12 Kanda, Chiyoda-ku, Tokyo |
| (3) Title and name of the representative | President and CEO Masao Yamaguchi |
| (4) Business content | Contract analysis of genetic information Data analysis of genetic information and system development Training service for researchers and medical personnel |
| (5) Capital | 30 million yen (as of the end of January 2016) |
| (6) Date of establishment | March 8, 2010 |
■ Outline of shares to be acquired and acquisition price
In January 2016, we undertook a part of the third-party allotment of shares implemented by Ameliev and acquired the common stock of Ameliev (equity ratio 10.0%).
■ Future outlook
The impact on the Company's consolidated financial results for the fiscal year ending September 2016 will be minor.
-Contact for inquiries from the press-
Euglena Co., Ltd. Public Relations and IR Division